Psivant Therapeutics

Biotech & Life Sciences · Boston, United States · Founded 2022

Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a computation-first approach to drug design

Valuation $100–500M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Psivant Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2022
Headquarters: Boston, United States
Employees: 37
Open positions: None listed
Dealroom signal: 50.0

Website ↗LinkedIn ↗

client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorAI Drug DiscoverysectorTechbiosectorDT and LSsectorscience-based

Valuation & funding

Psivant Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2025	$48M	$190M	Roivant Sciences · Lightstone Ventures · Eurofarma · YK Bioventures	↗

Showing 1 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

Year	Employees
2026	36
2025	23
2024	23
2023	23

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Psivant Therapeutics website traffic

Latest recorded traffic for Psivant Therapeutics is 600 monthly website visits, down 80.6% over the last three months. Psivant Therapeutics's team grew 60.9% over the past year.

Latest monthly visits600 3-month web change-80.6% 1-year team growth+60.9%

Monthly website visits36 observations · Feb 2023–Jan 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Psivant Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CBCoefficient bioAI models and agentic platforms for biopharma.	New York City, United States	Acquired	6	—	$400M
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
INInVirtuoLabsModular AI solutions accelerating drug discovery with predictive models and generative simulations	Lugano, Switzerland	Operational
XTXaira TherapeuticsIntegrated biotechnology company focusing on leveraging artificial intelligence to transform drug discovery and development	Brisbane, United States	Operational
SMSuperluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created	Boston, United States	Operational
PAPartexFirst digital pharma platform that is set to be the largest AI-powered Drug Assets Manager	Eschborn, Germany	Operational
AUAutomeratxDeveloping the next evolution in degradation platforms	Singapore	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Psivant Therapeutics's talent

Book a demo to see the people

Team profiled 5 named & role-tagged

Founders /100 quality score

Key operators 1 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Psivant Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Series A 5 investors entered at this stage

Lightstone Ventures

Samsara BioCapital

Roivant Sciences

Eurofarma

YK Bioventures

Global footprint

Where Psivant Therapeutics has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

In the news

Latest news about Psivant Therapeutics

Recent press, funding announcements, and product moves mentioning Psivant Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Psivant Therapeutics

An AI-synthesized read of the highest-engagement posts about Psivant Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Psivant Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.